Pay in 4 interest-free payments of $5.84 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
(PubMed) Burk K
Given these benefits, GLP-1s are a powerful tool in the fight against obesity and metabolic dysfunction and have revolutionized treatments
In addition to weight loss, some GLP-1 medications can reduce cardiovascular risk and help treat conditions such as fatty liver disease and obstructive sleep apnea
Professional Customer Support
US$ 24.07
US$ 25.51
US$ 20.35
